Neurocrine Biosciences (NASDAQ: NBIX)
Key Data Points
Neurocrine Biosciences Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Neurocrine Biosciences Company Info
Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases.
News & Analysis
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
Why Neurocrine Biosciences Stock Sank Today
Neurocrine Biosciences Reports Mixed Q4
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.
Neurocrine Tops Expectations in Q3
The biotech company reported strong growth in both revenue and earnings, driven largely by the sales of its flagship drug, Ingrezza.
Why Neurocrine Biosciences Stock Was Tumbling This Week
The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea.
Neurocrine Biosciences' Revenue and Adjusted Income Surge
Sales of the biopharmaceutical's flagship drug rose by 32% in Q2.
Why Neurocrine Biosciences Shares Fell Nearly 10% Today
Investors have grown weary of unpredictable profitability and unexpected expenses.
3 Biotech Stocks With Huge Catalysts This Fall
Clinical trial results expected this fall could send shares of these stocks screaming higher, or lower.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.